Show simple item record

dc.contributor.authorJohnson, Matthewen_US
dc.contributor.authorFernandez, Francescaen_US
dc.contributor.authorColson, Natalieen_US
dc.contributor.authorGriffiths, Lynen_US
dc.contributor.editorDimitri Mikhailidisen_US
dc.date.accessioned2017-05-03T14:06:07Z
dc.date.available2017-05-03T14:06:07Z
dc.date.issued2007en_US
dc.date.modified2009-01-23T05:37:53Z
dc.identifier.issn14656566en_US
dc.identifier.doi10.1517/14656566.8.12.1821en_AU
dc.identifier.urihttp://hdl.handle.net/10072/17847
dc.description.abstractMigraine is a common idiopathic primary headache disorder with significant mental, physical and social health implications. Accompanying an intense unilateral pulsating head pain other characteristic migraine symptoms include nausea, emesis, phonophobia, photophobia and in approximately 20-30% of migraine cases, neurologic disturbances associated with the aura phase. Although selective serotonin (5-HT) receptor agonists (i.e., 5-HT(1B/1D)) are successful in alleviating migrainous symptoms in < or = 70% of known sufferers, for the remaining 30%, additional migraine abortive medications remain unsuccessful, not tested or yet to be identified. Genetic characterization of the migrainous disorder is making steady progress with an increasing number of genomic susceptibility loci now identified on chromosomes 1q, 4q, 5q, 6p, 11q, 14q, 15q, 17p, 18q, 19p and Xq. The 4q, 5q, 17p and 18q loci involve endophenotypic susceptibility regions for various migrainous symptoms. In an effort to develop individualized pharmacotherapeutics, the identification of these migraine endophenotypic loci may well be the catalyst needed to aid in this goal. In this review the authors discuss the present treatment of migraine, known genomic susceptibility regions and results from migraine (genetic) association studies. The authors also discuss pharmacogenomic considerations for more individualized migraine prophylactic treatments.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherInforma Healthcareen_US
dc.publisher.placeLondon UKen_US
dc.publisher.urihttp://www.informapharmascience.com/en_AU
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofpagefrom1821en_US
dc.relation.ispartofpageto1835en_US
dc.relation.ispartofissue12en_US
dc.relation.ispartofjournalExpert Opinion Pharmacotherapyen_US
dc.relation.ispartofvolume8en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchcode320799en_US
dc.titleA pharmacogenomic evaluation of migraine therapyen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.facultyGriffith Health, School of Medical Scienceen_US
gro.date.issued2007
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record